Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis

被引:7
|
作者
Mori, Kazuma [1 ,8 ]
Akiyama, Yukinori [2 ]
Tanaka, Marenao [1 ]
Sato, Tatsuya [1 ,3 ]
Endo, Keisuke [1 ]
Hosaka, Itaru [4 ]
Hanawa, Nagisa [5 ]
Sakamoto, Naoya [6 ,7 ]
Furuhashi, Masato [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Cardiovasc Renal & Metab Med, S-1,W-16,Chuo Ku, Sapporo 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Japan
[3] Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Japan
[4] Sapporo Med Univ, Sch Med, Dept Cardiovasc Surg, Sapporo, Japan
[5] Keijinkai Maruyama Clin, Dept Hlth Checkup & Promot, Sapporo, Japan
[6] Hokkaido Univ, Fac Med, Dept Gastroenterol & Hepatol, Sapporo, Japan
[7] Grad Sch Med, Sapporo, Japan
[8] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Japan
基金
日本学术振兴会;
关键词
clustering; machine learning; metabolic dysfunction-associated fatty liver disease (MAFLD); metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); CLINICAL-PRACTICE GUIDELINES; DELPHI CONSENSUS STATEMENT; ALCOHOL-CONSUMPTION; HEPATITIS-C; INDEX; RISK; INDIVIDUALS; PREVALENCE; MECHANISMS; FACTORIAL;
D O I
10.1111/jgh.16552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimNew nomenclature of steatotic liver disease (SLD) including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) has recently been proposed. We investigated clustering analyses to decipher the complex landscape of SLD pathologies including the former nomenclature of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsJapanese individuals who received annual health checkups including abdominal ultrasonography (n = 15 788, men/women: 10 250/5538, mean age: 49 years) were recruited.ResultsThe numbers of individuals with SLD, MASLD, MetALD, ALD, NAFLD, and MAFLD were 5603 (35.5%), 4227 (26.8%), 795 (5.0%), 324 (2.1%), 3982 (25.8%), and 4946 (31.3%), respectively. Clustering analyses using t-distributed stochastic neighbor embedding and K-means to visually represent interconnections in SLDs uncovered five cluster formations. MASLD and NAFLD mainly shared three clusters including (i) low alcohol intake with relatively low-grade obesity; (ii) obesity with dyslipidemia; and (iii) dysfunction of glucose metabolism. Both MetALD and ALD displayed one distinct cluster intertwined with alcohol consumption. MAFLD widely shared all of the five clusters. In machine learning-based analyses using algorithms of random forest and extreme gradient boosting and receiver operating characteristic curve analyses, fatty liver index (FLI), calculated by body mass index, waist circumference, and levels of gamma-glutamyl transferase and triglycerides, was selected as a useful feature for SLDs.ConclusionsThe new nomenclature of SLDs is useful for obtaining a better understanding of liver pathologies and for providing valuable insights into predictive factors and the dynamic interplay of diseases. FLI may be a noninvasive predictive marker for detection of SLDs. 1 image
引用
收藏
页码:1382 / 1393
页数:12
相关论文
共 50 条
  • [11] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [12] Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease
    Suzuki, Keito
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Takahashi, Yuka
    Yamazaki, Yudai
    Uchihara, Naoki
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Keitoku, Taisei
    Okada, Risa
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Izumi, Namiki
    HEPATOLOGY RESEARCH, 2024, 54 (06) : 600 - 605
  • [13] Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease
    Gulati, Reeti
    Moylan, Cynthia A.
    Wilder, Julius
    Wegermann, Kara
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (02):
  • [14] Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Portincasa, Piero
    Baffy, Gyorgy
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 35 - 39
  • [15] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [16] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025, : 94 - 103
  • [17] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [18] Lipoic acid in metabolic dysfunction-associated steatotic liver disease: a review
    Fangli Liu
    Jingjing Lv
    Yuanyuan Chen
    Linfeng Wang
    Zhuoxin Liu
    Xingke Li
    Nutrition & Metabolism, 22 (1)
  • [19] Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease
    Matteo, Maria Valeria
    Gualtieri, Loredana
    Bove, Vincenzo
    Palumbo, Giulia
    Pontecorvi, Valerio
    De Siena, Martina
    Barbaro, Federico
    Spada, Cristiano
    Boskoski, Ivo
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (08) : 397 - 405
  • [20] Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Pei, Yiying
    Goh, George Boon-Bee
    GUT AND LIVER, 2025, 19 (01) : 8 - 18